The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases.

Zilli, Thomas; Dirix, Piet; Heikkilä, Reino; Liefhooghe, Nick; Siva, Shankar; Gomez-Iturriaga, Alfonso; Everaerts, Wouter; Otte, François; Shelan, Mohamed; Mercier, Carole; Achard, Vérane; Thon, Kristian; Stellamans, Karin; Moon, Daniel; Conde-Moreno, Antonio; Papachristofilou, Alexandros; Scorsetti, Marta; Gückenberger, Matthias; Ameye, Filip; Zapatero, Almudena; ... (2021). The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases. European urology focus, 7(2), pp. 241-244. Elsevier 10.1016/j.euf.2020.12.010

[img] Text
1-s2.0-S2405456920303126-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (808kB)

Optimal local treatment for nodal oligorecurrent prostate cancer is unknown. The randomized phase 2 PEACE V-STORM trial will explore the best treatment approach in this setting. Early results on the acute toxicity profile are projected to be published in quarter 3, 2021.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Shelan, Mohamed

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2405-4569

Publisher:

Elsevier

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

04 Feb 2021 15:06

Last Modified:

05 Dec 2022 15:45

Publisher DOI:

10.1016/j.euf.2020.12.010

PubMed ID:

33386290

BORIS DOI:

10.48350/151170

URI:

https://boris.unibe.ch/id/eprint/151170

Actions (login required)

Edit item Edit item
Provide Feedback